Copyright Reports & Markets. All rights reserved.

Global Primary Sclerosing Cholangitis Treatment Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Primary Sclerosing Cholangitis Treatment Market Overview

    • 1.1 Product Overview and Scope of Primary Sclerosing Cholangitis Treatment
    • 1.2 Classification of Primary Sclerosing Cholangitis Treatment by Types
      • 1.2.1 Global Primary Sclerosing Cholangitis Treatment Revenue Comparison by Types (2019-2024)
      • 1.2.2 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Types in 2018
      • 1.2.3 Liver Transplantation Operation
      • 1.2.4 UDCA Drugs
      • 1.2.5 PSC Drugs
    • 1.3 Global Primary Sclerosing Cholangitis Treatment Market by Application
      • 1.3.1 Global Primary Sclerosing Cholangitis Treatment Market Size and Market Share Comparison by Applications (2014-2024)
      • 1.3.2 Hospital
      • 1.3.3 Clinics
      • 1.3.4 Other
    • 1.4 Global Primary Sclerosing Cholangitis Treatment Market by Regions
      • 1.4.1 Global Primary Sclerosing Cholangitis Treatment Market Size (Million USD) Comparison by Regions (2014-2024)
      • 1.4.1 North America (USA, Canada and Mexico) Primary Sclerosing Cholangitis Treatment Status and Prospect (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Primary Sclerosing Cholangitis Treatment Status and Prospect (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Primary Sclerosing Cholangitis Treatment Status and Prospect (2014-2024)
      • 1.4.4 South America (Brazil, Argentina, Colombia) Primary Sclerosing Cholangitis Treatment Status and Prospect (2014-2024)
      • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Primary Sclerosing Cholangitis Treatment Status and Prospect (2014-2024)
    • 1.5 Global Market Size of Primary Sclerosing Cholangitis Treatment (2014-2024)

    2 Company Profiles

    • 2.1 Allergan
      • 2.1.1 Business Overview
      • 2.1.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Allergan Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 Epic Pharma
      • 2.2.1 Business Overview
      • 2.2.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 Epic Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 Mylan
      • 2.3.1 Business Overview
      • 2.3.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 Mylan Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 Glenmark
      • 2.4.1 Business Overview
      • 2.4.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 Glenmark Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 Daewoong Pharmaceutical
      • 2.5.1 Business Overview
      • 2.5.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 Impax Laboratories
      • 2.6.1 Business Overview
      • 2.6.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Impax Laboratories Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 Lannett
      • 2.7.1 Business Overview
      • 2.7.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 Lannett Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 Dr. Falk Pharma
      • 2.8.1 Business Overview
      • 2.8.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 Teva Pharmaceuticals
      • 2.9.1 Business Overview
      • 2.9.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.10 Mitsubishi Tanabe Pharma
      • 2.10.1 Business Overview
      • 2.10.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.11 Gilead Sciences
      • 2.11.1 Business Overview
      • 2.11.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.11.2.1 Product A
        • 2.11.2.2 Product B
      • 2.11.3 Gilead Sciences Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.12 NGM Biopharmaceuticals
      • 2.12.1 Business Overview
      • 2.12.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.12.2.1 Product A
        • 2.12.2.2 Product B
      • 2.12.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.13 Bruschettini
      • 2.13.1 Business Overview
      • 2.13.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.13.2.1 Product A
        • 2.13.2.2 Product B
      • 2.13.3 Bruschettini Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.14 Durect Corporation
      • 2.14.1 Business Overview
      • 2.14.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.14.2.1 Product A
        • 2.14.2.2 Product B
      • 2.14.3 Durect Corporation Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.15 Intercept Pharmaceuticals
      • 2.15.1 Business Overview
      • 2.15.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.15.2.1 Product A
        • 2.15.2.2 Product B
      • 2.15.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.16 Acorda Therapeutics
      • 2.16.1 Business Overview
      • 2.16.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.16.2.1 Product A
        • 2.16.2.2 Product B
      • 2.16.3 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.17 Shanghai Pharma
      • 2.17.1 Business Overview
      • 2.17.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.17.2.1 Product A
        • 2.17.2.2 Product B
      • 2.17.3 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.18 Conatus Pharmaceuticals
      • 2.18.1 Business Overview
      • 2.18.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.18.2.1 Product A
        • 2.18.2.2 Product B
      • 2.18.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.19 Shire Plc
      • 2.19.1 Business Overview
      • 2.19.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.19.2.1 Product A
        • 2.19.2.2 Product B
      • 2.19.3 Shire Plc Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.20 Grindeks
      • 2.20.1 Business Overview
      • 2.20.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.20.2.1 Product A
        • 2.20.2.2 Product B
      • 2.20.3 Grindeks Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.21 Sirnaomics
      • 2.21.1 Business Overview
      • 2.21.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.21.2.1 Product A
        • 2.21.2.2 Product B
      • 2.21.3 Sirnaomics Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
    • 2.22 Shenzhen HighTide Biopharmaceuticals
      • 2.22.1 Business Overview
      • 2.22.2 Primary Sclerosing Cholangitis Treatment Type and Applications
        • 2.22.2.1 Product A
        • 2.22.2.2 Product B
      • 2.22.3 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Primary Sclerosing Cholangitis Treatment Market Competition, by Players

    • 3.1 Global Primary Sclerosing Cholangitis Treatment Revenue and Share by Players (2014-2019)
    • 3.2 Market Concentration Rate
      • 3.2.1 Top 5 Primary Sclerosing Cholangitis Treatment Players Market Share
      • 3.2.2 Top 10 Primary Sclerosing Cholangitis Treatment Players Market Share
    • 3.3 Market Competition Trend

    4 Global Primary Sclerosing Cholangitis Treatment Market Size by Regions

    • 4.1 Global Primary Sclerosing Cholangitis Treatment Revenue and Market Share by Regions
    • 4.2 North America Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 4.3 Europe Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 4.5 South America Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)

    5 North America Primary Sclerosing Cholangitis Treatment Revenue by Countries

    • 5.1 North America Primary Sclerosing Cholangitis Treatment Revenue by Countries (2014-2019)
    • 5.2 USA Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 5.3 Canada Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 5.4 Mexico Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)

    6 Europe Primary Sclerosing Cholangitis Treatment Revenue by Countries

    • 6.1 Europe Primary Sclerosing Cholangitis Treatment Revenue by Countries (2014-2019)
    • 6.2 Germany Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 6.3 UK Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 6.4 France Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 6.5 Russia Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 6.6 Italy Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)

    7 Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue by Countries

    • 7.1 Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue by Countries (2014-2019)
    • 7.2 China Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 7.3 Japan Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 7.4 Korea Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 7.5 India Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)

    8 South America Primary Sclerosing Cholangitis Treatment Revenue by Countries

    • 8.1 South America Primary Sclerosing Cholangitis Treatment Revenue by Countries (2014-2019)
    • 8.2 Brazil Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 8.3 Argentina Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 8.4 Colombia Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)

    9 Middle East and Africa Revenue Primary Sclerosing Cholangitis Treatment by Countries

    • 9.1 Middle East and Africa Primary Sclerosing Cholangitis Treatment Revenue by Countries (2014-2019)
    • 9.2 Saudi Arabia Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 9.3 UAE Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 9.4 Egypt Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 9.5 Nigeria Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
    • 9.6 South Africa Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)

    10 Global Primary Sclerosing Cholangitis Treatment Market Segment by Type

    • 10.1 Global Primary Sclerosing Cholangitis Treatment Revenue and Market Share by Type (2014-2019)
    • 10.2 Global Primary Sclerosing Cholangitis Treatment Market Forecast by Type (2019-2024)
    • 10.3 Liver Transplantation Operation Revenue Growth Rate (2014-2024)
    • 10.4 UDCA Drugs Revenue Growth Rate (2014-2024)
    • 10.5 PSC Drugs Revenue Growth Rate (2014-2024)

    11 Global Primary Sclerosing Cholangitis Treatment Market Segment by Application

    • 11.1 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Application (2014-2019)
    • 11.2 Primary Sclerosing Cholangitis Treatment Market Forecast by Application (2019-2024)
    • 11.3 Hospital Revenue Growth (2014-2019)
    • 11.4 Clinics Revenue Growth (2014-2019)
    • 11.5 Other Revenue Growth (2014-2019)

    12 Global Primary Sclerosing Cholangitis Treatment Market Size Forecast (2019-2024)

    • 12.1 Global Primary Sclerosing Cholangitis Treatment Market Size Forecast (2019-2024)
    • 12.2 Global Primary Sclerosing Cholangitis Treatment Market Forecast by Regions (2019-2024)
    • 12.3 North America Primary Sclerosing Cholangitis Treatment Revenue Market Forecast (2019-2024)
    • 12.4 Europe Primary Sclerosing Cholangitis Treatment Revenue Market Forecast (2019-2024)
    • 12.5 Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue Market Forecast (2019-2024)
    • 12.6 South America Primary Sclerosing Cholangitis Treatment Revenue Market Forecast (2019-2024)
    • 12.7 Middle East and Africa Primary Sclerosing Cholangitis Treatment Revenue Market Forecast (2019-2024)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Description

      Scope of the Report:
      The global Primary Sclerosing Cholangitis Treatment market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Primary Sclerosing Cholangitis Treatment.
      Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
      This report studies the Primary Sclerosing Cholangitis Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Primary Sclerosing Cholangitis Treatment market by product type and applications/end industries.

      Market Segment by Companies, this report covers
      Allergan
      Epic Pharma
      Mylan
      Glenmark
      Daewoong Pharmaceutical
      Impax Laboratories
      Lannett
      Dr. Falk Pharma
      Teva Pharmaceuticals
      Mitsubishi Tanabe Pharma
      Gilead Sciences
      NGM Biopharmaceuticals
      Bruschettini
      Durect Corporation
      Intercept Pharmaceuticals
      Acorda Therapeutics
      Shanghai Pharma
      Conatus Pharmaceuticals
      Shire Plc
      Grindeks
      Sirnaomics
      Shenzhen HighTide Biopharmaceuticals

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      Liver Transplantation Operation
      UDCA Drugs
      PSC Drugs

      Market Segment by Applications, can be divided into
      Hospital
      Clinics
      Other
      Buy now